The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sampling Variability of Liver Fibrosis in Chronic Hepatitis C
Bedossa, P., Dargère, D., & Paradis, V. (2003) · Hepatology · doi:10.1016/j.hep.2003.09.022 · Cited by 2,376
Tissue inhibitors of metalloproteinases: evolution, structure and function
Brew, K., Dinakarpandian, D., & Nagase, H. (2000) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(99)00279-4 · Cited by 1,908
Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase
Strongin, A. Y., Collier, I., Bannikov, G., Marmer, B. L., Grant, G. A., & Goldberg, G. I. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.10.5331 · Cited by 1,593
Smit, J. J. M., Schinkel, A. H., Elferink, R. P. J. O., Groen, A. K., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., Ottenhoff, R., van der Lugt, N. M. T., van Roon, M. A., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90380-9 · Cited by 1,456
Serum markers detect the presence of liver fibrosis: A cohort study
Rosenberg, W. M. C., Voelker, M., Thiel, R., Becka, M., Burt, A., Schuppan, D., Hubscher, S., Roskams, T., Pinzani, M., & Arthur, M. J. P. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.08.052 · Cited by 1,102
Self-citationHistory, Heterogeneity, Developmental Biology, and Functions of Quiescent Hepatic Stellate Cells
Geerts, A. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-17550 · Cited by 740
Extracellular Matrix Degradation and the Role of Hepatic Stellate Cells
Benyon, R. C., & Arthur, M. J. P. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-17552 · Cited by 485
Butler, G. S., Butler, M. J., Atkinson, S. J., Will, H., Tamura, T., van Westrum, S. S., Crabbe, T., Clements, J., d'Ortho, M.-P., & Murphy, G. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.2.871 · Cited by 470
Fickert, P., Fuchsbichler, A., Wagner, M., Zollner, G., Kaser, A., Tilg, H., Krause, R., Lammert, F., Langner, C., Zatloukal, K., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.009 · Cited by 468
Self-citationMurphy, F. R., Issa, R., Zhou, X., Ratnarajah, S., Arthur, M. J. P., Benyon, C., Iredale, J. P., & Nagase, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111490200 · Cited by 432 · cited 7×
“It occurs on the cell surface, requires complex formation with TIMP-2 and membrane-anchored MMP-14 [21], and the interaction of HSC/MF with hepatocytes [22].”
BackgroundInfluential
Cited by
Mederacke, I., Hsu, C. C., Troeger, J. S., Huebener, P., Mu, X., Dapito, D. H., Pradere, J.-P., & Schwabe, R. F. (2013) · Nature Communications · doi:10.1038/ncomms3823 · Cited by 1,443
Hepatic fibrosis: concept to treatment
Trautwein, C., Friedman, S. L., Schuppan, D., & Pinzani, M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.039 · Cited by 677
“Mdr2 KO mice that lack the hepatocyte phospholipid flippase Mdr2 mimic human primary sclerosing cholangitis as a model of spontaneous biliary fibrosis progression (Mdr2 KO) [46], while administration of toxins (CCl4 and/or thioacetamide) induces a progressive parenchymal fibrosis, which after long-term administration,…”
BackgroundSelf-citationTherapy for Fibrotic Diseases: Nearing the Starting Line
Friedman, S. L., Sheppard, D., Duffield, J. S., & Violette, S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004700 · Cited by 655
Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets
Zhang, C.-Y., Yuan, W.-G., He, P., Lei, J.-H., & Wang, C.-X. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i48.10512 · Cited by 594
Evolving challenges in hepatic fibrosis
Friedman, S. L. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.97 · Cited by 581
Liver fibrosis: Direct antifibrotic agents and targeted therapies
Schuppan, D., Ashfaq-Khan, M., Yang, A. T., & Kim, Y. O. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.04.006 · Cited by 435
Self-citationAASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
Bowlus, C. L., Arrivé, L., Bergquist, A., Deneau, M., Forman, L., Ilyas, S. I., Lunsford, K. E., Martinez, M., Sapisochin, G., Shroff, R., et al. (2023) · Hepatology · doi:10.1002/hep.32771 · Cited by 428
Experimental models of liver fibrosis
Crespo Yanguas, S., Cogliati, B., Willebrords, J., Maes, M., Colle, I., van den Bossche, B., de Oliveira, C. P. M. S., Andraus, W., Alves, V. A., Leclercq, I., et al. (2016) · Archives of Toxicology · doi:10.1007/s00204-015-1543-4 · Cited by 350
Hepatic fibrosis: molecular mechanisms and drug targets
Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P., & Mallat, A. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095906 · Cited by 325
An, P., Wei, L.-L., Zhao, S., Sverdlov, D. Y., Vaid, K. A., Miyamoto, M., Kuramitsu, K., Lai, M., & Popov, Y. V. (2020) · Nature Communications · doi:10.1038/s41467-020-16092-0 · Cited by 319
Self-citationCell and tissue engineering for liver disease
Bhatia, S. N., Underhill, G. H., Zaret, K. S., & Fox, I. J. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3005975 · Cited by 309
Targeting Liver Fibrosis: Strategies for Development and Validation of Antifibrotic Therapies†
Popov, Y., & Schuppan, D. (2009) · Hepatology · doi:10.1002/hep.23123 · Cited by 296
Self-citationIkenaga, N., Peng, Z.-W., Vaid, K. A., Liu, S. B., Yoshida, S., Sverdlov, D. Y., Mikels-Vigdal, A., Smith, V., Schuppan, D., & Popov, Y. V. (2017) · Gut · doi:10.1136/gutjnl-2016-312473 · Cited by 295
Self-citationFunction and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein)
Oude Elferink, R. P. J., & Paulusma, C. C. (2007) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-006-0062-9 · Cited by 282
Animal models to study bile acid metabolism
Li, J., & Dawson, P. A. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.05.011 · Cited by 255
Liu, S. B., Ikenaga, N., Peng, Z., Sverdlov, D. Y., Greenstein, A., Smith, V., Schuppan, D., & Popov, Y. (2016) · The FASEB Journal · doi:10.1096/fj.14-268425 · Cited by 224
Self-citationMacrophages contribute to the pathogenesis of sclerosing cholangitis in mice
Guicciardi, M. E., Trussoni, C. E., Krishnan, A., Bronk, S. F., Lorenzo Pisarello, M. J., O'Hara, S. P., Splinter, P. L., Gao, Y., Vig, P., Revzin, A., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.018 · Cited by 183
Patsenker, E., Popov, Y., Stickel, F., Schneider, V., Ledermann, M., Sägesser, H., Niedobitek, G., Goodman, S. L., & Schuppan, D. (2009) · Hepatology · doi:10.1002/hep.23144 · Cited by 174
Self-citationRecurrence and rejection in liver transplantation for primary sclerosing cholangitis
Fosby, B. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i1.1 · Cited by 175
Yoshida, S., Ikenaga, N., Liu, S. B., Peng, Z.-W., Chung, J., Sverdlov, D. Y., Miyamoto, M., Kim, Y. O., Ogawa, S., Arch, R. H., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.038 · Cited by 164
Self-citationYang, A.-T., Kim, Y.-O., Yan, X.-Z., Abe, H., Aslam, M., Park, K.-S., Zhao, X.-Y., Jia, J.-D., Klein, T., You, H., et al. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.12.005 · Cited by 144
Self-citationPopov, Y., Sverdlov, D. Y., Bhaskar, K. R., Sharma, A. K., Millonig, G., Patsenker, E., Krahenbuhl, S., Krahenbuhl, L., & Schuppan, D. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00394.2009 · Cited by 136
Self-citationWeng, S.-Y., Wang, X., Vijayan, S., Tang, Y., Kim, Y. O., Padberg, K., Regen, T., Molokanova, O., Chen, T., Bopp, T., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.01.028 · Cited by 128
Self-citationNovel therapeutic targets in primary biliary cirrhosis
Dyson, J. K., Hirschfield, G. M., Adams, D. H., Beuers, U., Mann, D. A., Lindor, K. D., & Jones, D. E. J. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.12 · Cited by 120
Peng, Z., Ikenaga, N., Liu, S. B., Sverdlov, D. Y., Vaid, K. A., Dixit, R., Weinreb, P. H., Violette, S., Sheppard, D., Schuppan, D., et al. (2016) · Hepatology · doi:10.1002/hep.28274 · Cited by 118
Self-citationWei, G., An, P., Vaid, K. A., Nasser, I., Huang, P., Tan, L., Zhao, S., Schuppan, D., & Popov, Y. V. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00041.2019 · Cited by 84
Self-citationSecondary sclerosing cholangitis in critically ill patients: current perspectives
Gudnason, H. O., & Björnsson, E. S. (2017) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s115518 · Cited by 66
Will we ever model PSC? – “It's hard to be a PSC model!”
Pollheimer, M. J., Trauner, M., & Fickert, P. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.04.014 · Cited by 66
Self-citationThe Origin and Fate of Liver Myofibroblasts
Kim, H. Y., Sakane, S., Eguileor, A., Carvalho Gontijo Weber, R., Lee, W., Liu, X., Lam, K., Ishizuka, K., Rosenthal, S. B., Diggle, K., et al. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.09.008 · Cited by 63
“…of cholestatic injury, Mdr2 – / – mice (de fi cient of canalicular phospholipid fl ippase, Mdr2/Abcb4, and develop disruption of bile duct tight junctions and basal membranes, bile leakage, and periportal cholestatic fi brosis), 62 that resembles PSC 63 – 68 and mimics MDR2 de fi ciency in patients.”
BackgroundThe Haploinsufficient Col3a1 Mouse as a Model for Vascular Ehlers-Danlos Syndrome
Cooper, T. K., Zhong, Q., Krawczyk, M., Tae, H.-J., Müller, G. A., Schubert, R., Myers, L. A., Dietz, H. C., Talan, M. I., & Briest, W. (2010) · Veterinary Pathology · doi:10.1177/0300985810374842 · Cited by 51
Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis
Pollheimer, M. J., Racedo, S., Mikels-Vigdal, A., Marshall, D., Bowlus, C., Lackner, C., Madl, T., Karlsen, T. H., Hov, J. R., Lyman, S. K., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.04.009 · Cited by 38
Self-citationCingolani, F., Liu, Y., Shen, Y., Wen, J., Farris, A. B., & Czaja, M. J. (2022) · Hepatology Communications · doi:10.1002/hep4.1867 · Cited by 18
Metadata
- Authors
- Popov, Y., Patsenker, E., Fickert, P., Trauner, M., & Schuppan, D.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2005-12
- Volume
- 43
- Issue
- 6
- Pages
- 1045-1054
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W1969051655
- Cited by
- 268
- References
- 36
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.